

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$ RBD
Agarwal N	DOD Augusta University #	HT94252310158	10066182	54505664	2/23/23	2/22/27	Androgen Deprivation Therapy Mediated Cardiovascular Disease and Vascular Aging in Men with Prostate Cancer: Racial Difference, and Role of NAD+	\$6,000
Agarwal N & Coletta A	NCI	1R01CA281759-01	10066516	59320180	9/1/23	8/31/28	Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression: A Double-Blind Randomized Controlled Trial	\$692,568
Andersen J	NCI Brigham Young University #	1R01CA279074-01	10071196	54505820	8/1/23	7/31/26	Advanced Sample Preparation, Separation and Multiplexed Analysis for In-Depth Proteome Profiling of More Than 1000 Single Cells Per Day	\$50,000
Andersen J	NIGMS	7R01GM147310-03	10070741	59320401	9/2/23	6/30/26	Regulation and Function of the Ubiquitin-Sensing Kinase TNK1	\$323,398
Ayer D	NCI	5R01CA222650-05 NCE	10048024	59314830	7/1/18	6/30/24	Nutrient Sensing and Transcriptional Regulation	\$200,193
Barnette P	NCI Public Health Institute on behalf of COG #	U10CA180886	10046887	50303391	10/26/15	6/30/30	Every Child Protocol: Registry, Eligibility Screening, Biology and Outcome Study	\$1,133

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Bass B	NIGMS	5R35GM1412 62-03	10057378	59317571	4/1/21	3/31/26	Elucidating Roles and Mechanisms of Double-Stranded RNA-Mediated Pathways	\$603,900
Bass B	NIGMS	3R35GM1412 62-03S1	10057378S3.1	59317572	4/1/23	3/31/26	Elucidating Roles and Mechanisms of Double-Stranded RNA-Mediated Pathways : Vitrobot Mark IV Equipment Supplement	\$53,996
Bass B & Jackman J (Ohio State University Comprehensive Cancer Center) & Stetson D (University of Washington) & Elde N (University of Utah)	NCI	5R01CA26041 4-04	10054782	59317091, 59317092, 59317093	9/1/20	8/31/25	Unlocking Evolutionarily Latent Immune Functions for Treating Disease	\$1,165,317
Baucom B	NIMH George Washington University #	5R01MH12916 9-02	10061326	54505296	3/14/22	2/28/27	RCT of a Parent-Focused Intervention to Reduce HIV Risk in Adolescent MSM	\$31,235
Beaudin A	NHLBI	5R01HL14708 1-05	10057561	59316772	3/1/19	2/29/24	Regulation of Tissue Resident Macrophage Development by IL-7R Signaling	\$381,250
Beaudin A	NHLBI	5R21HL15779 4-02	10061048	59318390	1/1/22	12/31/23	Regulation of Hematopoietic Stem Cell Function by Prenatal Folate Status	\$198,611
Bernard P & Varley K	NCI	5UH3CA26222 1-02	10062203	59009612	8/1/22	7/31/25	Validation of the MHC II Immune Activation Assay in Breast Cancer	\$344,474
Bettini M	NIAID	1R01AI17549 4-01	10068394	TBD	12/1/23	10/31/28	Mechanisms of T Cell Persistence during Chronic Autoimmunity	\$601,815

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Bettini M & Evavold B	NIAID	1R01AI17221 0-01A1	10066223	59319500	3/1/23	2/29/28	Biophysical Parameters of Self-Reactive T Cell Receptor Engagement in Type 1 Diabetes	\$749,474
Bettini M	NIAID	5R01AI13696 3-05 NCE	10054020	59316260	12/1/18	11/30/24	Microbiota Specific T Cell Selection	\$72,165
Bettini M	NIDDK	5R01DK11445 6-06 NCE	10054021	59316410	10/1/19	5/31/24	Self-Reactive T Cell Development in Type 1 Diabetes	\$127,782
Buckley S	NCI	5R37CA26263 5-03	10066214	59319100	8/1/21	7/31/26	Dissecting the Role Ubiquitin E3 Ligase UBR5 in Lymphomagenesis	\$544,191
Buckley S	NIAID	5R01AI15309 0-03	10066226	59319080	8/25/21	7/31/25	Role of E3 Ligase UBR5 in Alternative Splicing during B Cell Development and Activation	\$386,642
Burrows C	NIGMS	5R35GM1452 37-02	10064245	59318790	6/1/22	5/31/27	Chemical Modifications in Regulatory Regions of DNA and RNA	\$461,875
Cairns B	NIA	5R01AG06972 5-04	10056377	59317340, 59317341	9/30/20	5/31/25	Molecular, Epigenetic and Genomic Approaches to Understand Mechanisms of Aging in the Human Testis	\$381,250
Cairns B	HHMI	N/A	99999991	HHMI	9/1/00	1/30/29	HHMI Investigator Program	\$800,000
Cairns B & White K (Utah State University) & Polejaeva I (Utah State University)	NICHD Utah State University #	5R01HD09583 3-05	10051354	54504409	9/1/19	5/31/24	Identifying Epigenetic Chromatin and Transcriptomic Landscapes to Improve SCNT Development in an Animal Model	\$200,336
Cao E	NIDDK	5R01DK12859 2-03	10059736	59318170	9/20/21	8/31/25	Structures and Pharmacology of Cation-Chloride Cotransporters	\$335,500

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Cazalla D	NIGMS	5R35GM1442 41-02	10060311	59318360	2/16/22	1/31/27	Novel Functions for SM-Class RNAs in the Regulation of Gene Expression	\$384,479
Chaix A	NIA	5R01AG06599 3-05	10060225	59317391	1/2/21	5/31/24	Mechanisms by which Time-Restricted Feeding (TRF) Delays the Onset of Age-Related Declines in Health, Cognition, and Circadian Rhythms	\$381,250
Chaix A	NIA	3R01AG06599 3-05S1	10060225DS2 .4	59317393	1/2/21	5/31/24	Mechanisms by which Time-Restricted Feeding (TRF) Delays the Onset of Age-Related Declines in Health, Cognition, and Circadian Rhythms : Diversity Supplement (Fellow: Matsuzaki)	\$4,066
Chandrasekharan M	NIGMS	5R01GM1277 83-05 NCE	10044894	59314590, 59314591	5/1/18	4/30/24	Structure, Function and Regulation of the H2B Ubiquitin-Conjugating Complex	\$3,010
Chandrasekharan M	NHGRI	5R21HG01152 0-02 NCE	10056619	59317420	1/1/21	12/31/23	Versatile "Pan-Spike-In" Internal Reference Genome Methodology for Quantitative Chip-Seq Normalization	\$6,650
Chen M	NIAID	5R01AI13953 5-04	10050550	59315560	1/25/19	12/31/24	Targeted Depletion of Programmed Death-1 Positive Cells, a Method That Not Only Stops Autoimmune Attack but Also Preserves Adaptive Immunity	\$616,097

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Chittoria N	Alliance	AFT38	10045770	50303281	2/1/17	9/1/28	Randomized, Open-Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib plus Anti-HER2 Therapy plus Endocrine Therapy versus Anti-HER2 Therapy plus Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2+ Metastatic Breast Cancer	\$19,200
Christian J	NICHD	5R01HD06747 3-10 NCE	10045697	59309832	7/1/12	4/30/24	Novel Developmental Regulation of BMP and Nodal Signaling by TRIL	\$99,808
Christian J	NICHD	3R21HD10266 8-02S1 NCE	10057356DS1	59317511	8/1/21	3/31/24	Analysis of BMP Heterodimer Formation and Function : Diversity Supplement (Fellow: Sanchez)	\$25,657
Christian J & Babitt J (Dana-Farber Cancer Institute)	NIDDK Massachusetts General Hospital #	5R01DK12806 8-03	10057629	54903131	4/1/21	1/31/25	BMP Ligands in Heparin Regulation	\$274,387
Coletta A & Agarwal N	NCI	1R01CA28175 9-01	10066516	59320180	9/1/23	8/31/28	Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression: A Double-Blind Randomized Controlled Trial	\$692,568
Colman H	Alliance Brigham and Women's Hospital #	N/A	10031873	54901967	3/1/14	2/28/24	Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction	\$18,956

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Couriel D	NHLBI National Marrow Donor Program #	U24HL138660	10054352	54902797	6/1/19	6/1/26	Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation (CTRLALT-D)	\$257
Deans T	NCI	1DP2CA25000 6-01	10051197	59700260	9/20/19	5/31/24	Engineered Platelets for the Targeted Destruction of Circulating Tumor Cells	\$457,500
Deans T	NCI	3DP2CA25000 6-01S1	10051197DS1 .1	59700261	7/1/22	5/31/24	Engineered Platelets for the Targeted Destruction of Circulating Tumor Cells : Diversity Supplement (Fellow: Jepsen)	\$32,587
Deans T	NIBIB	1R01EB03385 1-01A1	10063091	59320110	8/1/23	7/31/27	Synthetic Circuits for Therapeutic Platelet Production and Immunomodulation	\$464,504
Del Fiol G	NHGRI Geisinger Health System #	5R01HG01179 9-03	10058480	54903260	8/10/21	5/31/26	Real-Time Genetic Diagnosis at the Point of Care	\$205,482
Del Fiol G	CDC	5NU58DP0067 70-03-00	10056812	59008424	6/30/20	6/29/25	Public Health and Health Systems Partnerships to Increase Colorectal Cancer Screening in Clinical Settings	\$600,000
Del Fiol G & Butler J (University of Utah) & Madara-Kelly K (Idaho State University)	NIGMS Idaho State University #	5R01GM1370 83-04	10052552	54504664	7/15/20	6/30/24	Timely Response to In-Hospital Deterioration through Design of Actionable Augmented Intelligence	\$250,333
Del Fiol G & Kawamoto K	NCI	1U24CA27458 2-01A1	10066803	59010301, 59010311	9/1/23	8/31/28	GARDE: Scalable Clinical Decision Support for Individualized Cancer Risk Management	\$818,820

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Del Fiol G & Wetter D	NIMHD	5U01MD01742 1-02 NCE	10062178	59009312	1/1/22	11/30/24	SCALE UP Utah II: Community-Academic Partnership to Address COVID-19 Testing and Vaccination among Utah Community Health Centers	\$751,185
Diehl K	NIGMS	5R35GM1430 80-03	10058769	59317910	7/15/21	5/31/26	Eavesdropping on the Conversation between Chromatin and Metabolism	\$381,250
Doherty J	NCI	26120180001 6I-P00002- 26100002-1	10046122	59900674	5/1/18	4/30/28	Utah Cancer Registry Continued Participation in the Surveillance, Epidemiology, and End Results Program	\$2,212,420
Doherty J	NCI Mayo Clinic Cancer Center, Rochester #	5R01CA24828 8-03	10056044	54903360	1/13/21	12/31/25	Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and Risk	\$41,431
Doherty J	NCI Brigham and Women's Hospital #	5R01CA25867 9-03	10057578	54903130	4/1/21	3/31/26	Changing Contraceptive Patterns and Ovarian Cancer Risk	\$15,021
Doherty J	NCI Winship Cancer Institute #	5R01CA21157 4-05 NCE	10059198	54504687	2/1/20	1/31/24	Genomic and Transcriptomic Analysis of Breast and Ovarian Cancers	\$5,010
Doherty J & Greene C (University of Colorado Cancer Center)	NCI University of Colorado Cancer Center #	5R01CA23717 0-05	10059912	54504742	1/1/21	3/31/25	Characterization of High-Grade Serous Ovarian Cancer Subtypes via Single-Cell Profiling	\$145,634

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Doherty J & Kushi L (Kaiser Permanente) & Bandera E (Rutgers Cancer Institute of New Jersey) & Gomez S (UCSF Helen Diller Family Comprehensive Cancer Center)	NCI	5R01CA24318 8-04	10054672	59317070, 59317320	7/1/20	6/30/25	Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival: An Integrative Approach	\$1,365,470
Doherty J & Kushi L (Kaiser Permanente) & Bandera E (Rutgers Cancer Institute of New Jersey) & Gomez S (UCSF Helen Diller Family Comprehensive Cancer Center)	NCI	3R01CA24318 8-03S2 NCE	10054672S2	59317074	7/1/22	6/30/25	Understanding Ovarian Cancer Outcomes in Patients Living in Mexico	\$155,678
Doherty J & Schildkraut J (Winship Cancer Institute)	NCI	5R01CA20085 4-06 NCE	10044180	59313390	10/1/16	12/31/23	Characterizing Molecular Subtypes of Ovarian Cancer in African-American Women	\$167,713
Ducker G	ACS	DBG-23- 1037804-01- TBE	10066936	51200208	7/1/23	6/30/25	Development of Stable Isotope Tracing to Quantify Lipid Metabolic Fluxes in Tumors	\$150,000
Edgar B	NIGMS	5R35GM1409 00-03	10057509	59317920	5/1/21	4/30/26	Regulation of Cell Growth and Proliferation	\$752,639
Edgar B	NIDDK	5R01DK12574 5-03	10058299	59317620	3/25/21	2/28/25	Sex Steroid Signaling and Adaptive Growth of the Intestine	\$472,704
Edgar B & Summers S	NIDDK	5R01DK13160 9-03	10061167	59318230	9/23/21	5/31/26	Role of Ceramides in the Intestinal Stem Cell	\$512,080
English J	NIGMS	1DP2GM1462 47-01	10058882	59009121	9/23/21	8/31/24	Directed Evolution of Cell-Type Specific On-Demand Signaling Control Systems	\$446,496

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Estabrooks P	NHLBI Hollings Cancer Center #	1R56HL15721 8A1 NCE	10067316	54505505	9/23/22	8/31/24	Implementing and Evaluating the Comprehensive Integration of Physical Activity into a Major Health System and Connecting Patients to Community-Based Physical Activity Programs	\$6,218
Evason K	ACS	RSG-22-014-01-CCB	10063331	51200199	7/1/22	6/30/26	Hepatic Stellate Cells in Liver Development and Cancer	\$196,500
Evavold B	NIAID	5R01AI14764 1-04	10054720	59316620	3/1/20	2/28/25	CD8 T-Cell Antigen Recognition during Chronic Infection	\$646,886
Evavold B	NIAID	5R01AI16983 5-02	10062444	59319210	9/19/22	7/31/27	Defining How TCR Strength of Signal Modulates Treg Function	\$607,401
Evavold B & Baker B (University of Notre Dame)	NIAID University of Notre Dame #	1R01AI17666 5-01	10066394	54505543	3/2/23	2/29/28	Mechanisms and Manipulation of Force Dependent Behavior in T Cell Biology	\$405,549
Evavold B & Bettini M	NIAID	1R01AI17221 0-01A1	10066223	59319500	3/1/23	2/29/28	Biophysical Parameters of Self-Reactive T Cell Receptor Engagement in Type 1 Diabetes	\$749,474
Evavold B & Williams M	NIAID	1R01AI17225 3-01A1	10066240	59319710, 59319711	4/1/23	3/31/28	Deconstructed T Cell Antigen Recognition: Separation of Affinity from Bond Lifetime	\$717,941
Fagerlin A	NIA University of Colorado Cancer Center #	5R01AG06669 8-03	10053691	54504903	2/15/21	1/31/26	Cannabis Use among Older Adults: Potential Risks and Benefits to an Aging Population	\$92,263
Finkelstein J	NHLBI	7R33HL14331 7-06	10068292	59319830	5/29/23	8/31/24	Comprehensive Health Informatics Engagement Framework for Pulmonary Rehab	\$749,701

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Florou V	NCI	5R21CA25243 6-02 NCE	10058205	59318000	7/15/21	6/30/24	APK Mutant: A Single Arm Phase II study of Cetuximab in Third Line for Mutant APC, TP53 and RAS patients with Refractory Metastatic Colorectal Cancer	\$190,425
Franzini R	NIGMS	5R35GM1383 35-04	10053655	59317010	8/1/20	5/31/25	Tools to Study Electrophilic Stress and Develop Covalent Drugs	\$305,000
Franzini R & Donato A (University of Utah)	NIA	5R21AG07449 8-02	10062509	59319310	9/5/22	8/31/24	Improving Healthspan Through Discovery of Potent NAMPT Activators from a DNA-Encoded Library	\$230,129
Funai K	NIGMS	5R01GM1446 13-03	10060606	59318220	9/15/21	7/31/25	PE in Modulation of Energy Flux Through OXPHOS	\$305,000
Funai K	NIDDK	5R01DK10739 7-07	10062116	59314113	5/1/22	4/30/26	Mitochondrial Membrane Lipids and Respiratory Efficiency	\$437,650
Gaffney D	ECOG-ACRIN	N/A	10038017	54902233	1/1/15	12/31/24	Phase III Randomized Study Comparing Perioperative Nivolumab versus Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	\$16,973
Gaffney D	NCI	5UG1CA2331 78-05	10047019	59007455	3/15/19	2/28/25	Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma	\$503,279
Gaffney D	NCI NRG #	5U10CA18086 8-10	10062367	54903429	3/1/21	2/28/25	NRG Oncology Network Group Operations Center	\$7,000

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Garrido-Laguna I & Carson W (Ohio State University Comprehensive Cancer Center) & Arnold S (Markey Cancer Center)	NCI Ohio State University Comprehensive Cancer Center #	4UM1CA186712-07	10068371	54505713	3/1/23	2/28/26	Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network	\$360,932
Garzon R	NCI	7R01CA240612-04	10068325	59319461	11/16/22	3/31/26	Biology and Targeting of Noncoding RNAs in Acute Myeloid Leukemia	\$171,267
Garzon R & Ranganathan P (Ohio State University) & Dorrance A	NHLBI	7R01HL163849-02	10068113	59319381	11/15/22	7/31/26	Developing Novel Therapies to Improve Blood Stem Cell Transplantation Outcomes	\$671,563
Gertz J	NCI	1R21CA270580-01A1	10065914	59319590	5/1/23	4/30/25	Mechanisms of Tamoxifen-Associated Endometrial Cancer Risk	\$215,869
Ghandehari H	NCI Versiti Wisconsin #	1R01CA268496-01A1	10064886	54903422	1/1/23	12/31/27	Function of MS4A3 in Normal and Malignant Hematopoiesis	\$106,489
Ghandehari H	NIEHS	5R01ES024681-13	10060601	59311651	9/28/07	11/30/26	Biological Fate and Biocompatibility of Silica-Based Nanoconstructs	\$501,303
Ghandehari H & Oottamasathien S (Dana-Farber Cancer Institute)	NCI	5R01CA227225-05 NCE	10049346	59315520	12/1/18	11/30/24	Localized Delivery of Glycosaminoclycan Ethers for the Treatment of Radiation-Induced Proctitis	\$94,104
Golic K	NIGMS	5R35GM136389-04	10053693	59316850	5/20/20	4/30/25	Chromosome Breakage, Pairing and Replication: Impacts on Cell Fate and Function	\$381,250

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Golkowski M	NIGMS	1R35GM1507 66-01	10067022	59319970	7/1/23	4/30/28	Integrated Mass Spectrometry-Based Chemoproteomic and Genomic Technologies for Studying Dynamic Kinase Interactomes	\$385,000
Grossmann A	NCI	5R37CA23063 0-04	10055611	59316820	7/1/20	6/30/25	Targeting Rheostatic Mechanisms of Melanoma Progression	\$341,867
Haecker H	NIAID	5R01AI17094 2-02	10063166	59318721	7/7/22	6/30/27	Phospho-Tyrosine-Based Signaling Module Controlling TLR-Mediated Inflammatory Disease	\$734,968
Hashibe M	NCI	5R01CA24432 6-04	10055606	59316980	7/1/20	6/30/25	Long-Term Adverse Outcomes among Rural Cancer Survivors in a Population-Based Cohort	\$476,842
Hashibe M	NCI	5R01CA26089 1-02	10063551	59318980	8/1/22	7/31/27	Identifying Cancer Recurrence with Novel Data Linkages with a Cancer Registry	\$639,749
Hashibe M & Okuyemi K	NCI	2R25CA24675 6-04	10064288	59206151	9/19/23	8/31/28	Utah Advanced Course On Cancer-Related Health Disparities Research, Mentoring, and Leadership	\$310,217

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Hess R & Majersik J (University of Utah)	NCATS	1UM1TR00440 9-01	10065484	59009891, 59009811, 59009821, 59009831, 59009841, 59009851, 59009861, 59009871, 59009881, 59009901, 59009911, 59009921, 59009931, 59009941, 59009951, 59009961, 59009971, 59009981	4/1/23	3/31/30	CTSA UM1 Program at University of Utah	\$5,461,665
Hilgendorf K	NIDDK	5R01DK13345 5-02	10063113	59318780	7/22/22	6/30/27	Ciliary Signaling Mechanisms Regulating White Adipose Tissue Expansion	\$385,000
Hill C	NIDDK	5R01DK12726 8-03	10059395	59318240, 59318241	9/25/21	7/31/26	Structural Insights to Insulin Receptor Ligands	\$383,950
Hill C & Schmidt E (University of Utah)	NSF	2203613	10063458	58503251, 58503250	7/1/22	6/30/25	Structure and Function of Animal Polyketide Synthases: Bridging Lipid and Polyketide Biology	\$240,999
Hill C & Ullman K & Sundquist W	NIGMS	2R01GM1120 80-09	10066736	59311435, 59311436, 59311437	7/19/23	5/31/27	ESCRT and MIT Complexes in Cytokinesis	\$364,826

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Hill J	NIDDK University of Nebraska, Lincoln #	5R01DK12565 1-04	10063047	54505122	7/15/20	4/30/25	Modifiable Predictors of Neural Vulnerabilities for Obesity	\$9,324
Hill J	NIDDK University of Nebraska, Lincoln #	R01DK116693 NCE	10063048	54505121	11/1/21	3/31/24	Executive Control and Adolescent Weight Trajectories	\$882
Hill J	NASD Fred and Pamela Buffett Cancer Center #	5U18DP00669 5-03	10063246	54505199	9/16/21	3/31/24	Translating Efficacious Pediatric Weight Management Interventions into Rural and Micropolitan Communities -	\$99,288
Holmen S	NCI	5R01CA12111 8-14	10056879	59317350	4/1/07	11/30/25	High-Throughput Model for Human Melanoma	\$260,775
Holmen S	NCI Duke University #	1R01CA27912 9-01	10065520	54505777	8/30/23	7/31/28	Role of Regulation and Subcellular Localization of GTP Biosynthesis in Melanoma Invasion and Metastasis	\$31,514
Holmen S	NINDS	5R01NS10781 0-05	10050275	59315800	4/15/19	3/31/24	Exploiting the Vulnerabilities in Mutant IDH Gliomas	\$333,594
Huang L	NINDS	1R01NS12665 2-01A1	10064783	59319600	3/1/23	2/29/28	Targeting P53-Mediated Ferroptosis in Glioma	\$384,583
Hughes A	NIA	5R01AG06137 6-05 NCE	10048966	59315230	9/1/18	5/31/24	Role of the Lysosome in Aging	\$29,634
Hughes A	NIGMS	5R35GM1196 94-08	10058321	59317650	8/1/16	5/31/26	Investigating the Mitochondrial-Derived Compartment Pathway	\$381,250
Hughes A	NIGMS	3R35GM1196 94-07S1 NCE	10058321TS1. 7	59317651	6/1/22	5/31/26	Investigating the Mitochondrial-Derived Compartment Pathway - Undergraduate Summer Research Supplement (Fellow: Ward)	\$2,713

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Hughes A	NIGMS	3R35GM1196 94-07S2 NCE	10058321TS2. 7	59317652	6/1/21	5/31/26	Investigating the Mitochondrial-Derived Compartment Pathway - Undergraduate Summer Research Supplement (Fellow: Makassa Agnes)	\$3,514
Hughes A & O'Donnell A (University of Pittsburgh)	NSF	2321625	10068355	58503475, 58503476	7/15/23	6/30/27	Alpha-Arrestins' Impact on Cellular Physiology	\$32,794
Hu-Lieskovan S	NCI Knight Cancer Institute #	5U10CA18088 8-10	10054446	54505490	7/19/19	2/29/24	SWOG Network Group Operations Center of the NCTN	\$39,591
Jones K	NCI	1U54CA23165 2-01 NCE	10048136		9/14/18	6/30/24	Targeting SS18-SSX Biology in Synovial Sarcomagenesis	\$592,587
Jones K/ Jones K	NCI	1U54CA23165 2-01 NCE	10048136	59700210	9/14/18	6/30/24	Targeting SS18-SSX Biology in Synovial Sarcomagenesis - Administrative Core	
Jones K	NCI	3U54CA23165 2-01S1 NCE	10048136S1.1	59700216	7/1/22	6/30/24	Establish the SS18-SSX Biology in Synovial Sarcoma Research Center (SBSSRC)	\$382,790
Judson-Torres R	NCI	5R01CA22989 6-03	10059584	59318110, 59318111	8/24/21	7/31/26	Nevus Associated MicroRNAs as Mediators of BRAF-Induced Growth Arrest and Biomarkers of Melanoma Progression	\$341,867
Judson-Torres R	NCI	3R01CA22989 6-03S1	10059584DS1 .3	59318112	8/24/21	7/31/26	Nevus Associated MicroRNAs as Mediators of BRAF-Induced Growth Arrest and Biomarkers of Melanoma Progression - Diversity Supplement (Fellow: Urquijo)	\$59,875

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Judson-Torres R & Zangle T	NCI	1R01CA27665 3-01A1	10067459	59320340, 59320341, 59320342	9/12/23	8/31/28	Development and Pre-Clinical Validation of Quantitative Imaging of Cell State Kinetics (QuICK) for Functional Precision Oncology	\$390,494
Kaphingst K	AHRQ Washington University #	1R01R01HS02 9310-01	10068264	54505748	9/1/23	6/30/27	Sustainable Solutions to Translating Best Practices for Informed Consent	\$70,683
Kaphingst K & Sigureddi M (Laura and Isaac Perlmutter Cancer Center at NYU Langone Health)	NCI	5U01CA23282 6-05 NCE	10048536	59007375	9/18/18	8/31/24	Leveraging an Electronic Medical Record Infrastructure to Identify Primary Care Patients Eligible for Genetic Testing for Hereditary Cancer and Evaluate Novel Cancer Genetics Service Delivery Models	\$681,545
Kaphingst K & Sigureddi M (Laura and Isaac Perlmutter Cancer Center at NYU Langone Health)	NCI	3U01CA23282 6-05S1 NCE	10048536S1.5	59008705	9/1/22	8/31/24	Investigation into the Reduction of Disparities in Identification of Eligible Primary Care Patients through Utilization of Natural Language Processing and Outreach to Patients Meeting Cancer Genetic Evaluation from Medically Underserved Communities	\$36,405
Kaphingst K & Mehlman M (Case Comprehensive Cancer Center)	NCATS Case Comprehensive Cancer Center #	5R01TR00424 5-02	10063075	54505423	8/5/22	4/30/26	Using Nudges to Recruit Human Subjects in Clinical and Translational Research	\$164,539
Kawamoto K	AHRQ	5R18HS02879 1-02	10061646	59318702	8/1/22	7/31/25	Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale	\$993,772

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Kawamoto K & Conroy M (University of Utah)	NIDDK	5R18DK12337 2-04	10055536	59316961, 59316951	7/1/20	6/30/25	Promoting Real World Implementation of an Evidence-Based Weight Management Intervention in Primary Care	\$605,483
Kawamoto K & Del Fiol G	NCI	1U24CA27458 2-01A1	10066803	59010301, 59010311	9/1/23	8/31/28	GARDE: Scalable Clinical Decision Support for Individualized Cancer Risk Management	\$818,820
Kepka D	NCI Klein Buendel #	5R01CA26803 7-02	10064117	54903316	9/8/22	8/31/27	#4Corners4Health: A Social Media Cancer Prevention Program for Rural Emerging Adults	\$110,110
Kepka D	NCI	1R01CA27997 3-01	10065815	59319690	5/15/23	4/30/28	PREVENT - Practice-Based Approaches to Promote HPV Vaccination	\$666,739
King A	NCI	7R37CA25915 6-03	10066084	59318861	3/1/23	2/28/25	Using Natural Language Processing and Crowdsourcing to Monitor and Evaluate Public Information and Communication Disparities About Colon Cancer	\$924,628
Kirchhoff A	NCI Massachusetts General Hospital #	5R01CA27138 0-02	10062251	54903298	6/1/22	3/31/27	Assessing the Effect of Virtual Navigation Interventions to Improve Health Insurance Literacy and Decrease Financial Burden: A CCSS Randomized Trial	\$114,088

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Kirchhoff A	NCI Kaiser Permanente #	5P01CA23343 2-04	10061350C1	54903099	9/15/20	6/30/25	Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancer Survivors - Project 2: Patterns of Care and Patient Experiences during Early Survivorship among AYA Cancer Survivors - Project 2: Patterns of Care and Patient Experiences during Early Survivorship among AYA Cancer Survivors	\$36,817
Kirchhoff A	NCI Kaiser Permanente #	5P01CA23343 2-04	10061350C2	54903100	9/15/20	6/30/25	Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancer Survivors - Project 3: Chronic Medical Conditions and Late Effects in the AYA Cancer Population - Project 3: Chronic Medical Conditions and Late Effects in the AYA Cancer Population	\$38,329
Kirchhoff A & Park E (Massachusetts General Hospital)	NCI	1R01CA27682 5-01A1	10066025	59319880	6/14/23	5/31/28	Randomized Controlled Trial to Improve Health Insurance Literacy and Surveillance among Young Adult Cancer Survivors	\$672,704
Knudsen B	NCI	1R21CA27738 1-01	10064452	59319490, 59319491	2/6/23	1/31/25	Pathomics Biomarkers for Stratification of Clear Kidney Cell Cancers	\$215,693
Knudsen B	DOD	W81XWH-21-1-0725 NCE	10058466	55900763	9/1/21	8/31/24	Analysis of Tissue Architecture to Identify Lethal Prostate Cancer in the Veteran Population	\$158,022

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Koh M	NCI	5R01CA26226 2-02	10061477	59318930	9/1/22	8/31/27	Role for the Novel HAF-NFkappaB Axis in Driving Obesity-Associated Liver Cancer	\$421,432
Kohli M	DOD Fred and Pamela Buffett Cancer Center #	W81XWH-21-1-0629	10058450	54505012	8/1/21	7/31/24	Neuropilin-2 Inhibitor as a Potent Therapy for Prostate Cancer Bone Metastasis	\$49,770
Kohli M & Demirci U (Stanford Cancer Institute (SCI)) & Cunningham B (University of Illinois)	NIBIB University of Illinois Urbana-Champaign #	5R01EB02980 5-04	10056814	54504679	7/15/20	3/31/24	Exosome Separation and Digital Resolution Detection of Blood-Based Nucleic Acid Biomarkers for Noninvasive Therapeutic Diagnostics in Cancer	\$60,581
Kohli M & Smith A (University of Illinois)	NIBIB University of Illinois Urbana-Champaign #	5R01EB03272 5-02	10062471	54505380	8/15/22	5/31/26	Discovery and Applied Research for Technological Innovations to Improve Human Health	\$81,820
Kohli M & Wang L (Moffitt Cancer Center)	NCI Moffitt Cancer Center #	R01CA212097-06 NCE	10056965	54903287	8/1/17	7/31/24	Cell Free Nucleic Acid-Based Biomarkers in Advanced Prostate Cancer	\$13,775
Kopecek J	NCI	5R01CA24671 6-13	10052824	59316600	7/1/11	11/30/24	Drug-Free Macromolecular Therapeutics	\$313,959
Kramer J	NIGMS	5R35GM1472 62-02	10062794	59318900	7/1/22	6/30/27	Synthetic Mucins in Epithelial Models to Probe Virus-Mucin Interactions	\$385,000
Kramer J	NSF	2300012	10067028	58503420	7/15/23	6/30/26	Synthetic Antifreeze Glycoproteins for Cellular Cryopreservation	\$162,618
Lam C	NCI	5R01CA22453 7-06	10045740	59314580	1/19/18	12/31/24	Affective Science and Smoking Cessation: Real Time Real World Assessment	\$600,108

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Leibold E	NHLBI	1R01HL16849 2-01	10065508	59319900	4/2/23	6/30/27	Cell Cycle Regulation of IRP2 Phosphorylation During Hematopoiesis	\$554,974
Lex A	NSF	1751238 NCE	10046819	58502563	1/1/18	3/31/24	CAREER: Enabling Reproducibility of Interactive Visual Data Analysis	\$66,936
Lex A	NSF	1751238 NCE	10046819S1	58502903	4/1/18	3/31/24	CAREER: Enabling Reproducibility of Interactive Visual Data Analysis : Administrative Supplement	\$129
Lex A	NSF	2213756	10066147	58503282, 58503283	7/1/22	6/30/25	Collaborative Research: CCRI: New: reVISIT: Scalable Empirical Evaluation of Interactive Visualizations	\$417,393
Lex A & Jones B (University of Utah)	NSF	1835904 NCE	10052486	58502665	1/1/19	12/31/23	Collaborative Research: Framework: Software: HDR: Reproducible Visual Analysis of Multivariate Networks with MultiNet	\$86,108
Lex A & Kogan M (University of Utah)	NSF	2041136 NCE	10058420	58502961, 58502962	1/1/21	6/30/24	EAGER: Understanding and Mitigating Misinformation in Visualizations on Social Media	\$9,149
Lim C	NCI	5R21CA24101 5-02 NCE	10056611	59317430	1/1/21	12/31/23	Re-Engineered Mitochondrially Targeted P53 Gene Therapy for Liver Cancer	\$236
Lim C	NCI	5R01CA24458 3-03	10056803	59316930, 59316931	1/1/21	12/31/25	Leukemia Cell-Specific Coiled-Coil Protein for Treatment of Chronic Myeloid Leukemia	\$341,867
Linder L	NCI Virginia Commonwealth University #	1R01CA28679 9-01	10062914	54505772	6/9/23	5/31/27	Randomized Controlled Trial using a Heuristic Tool to Improve Symptom Self-Management in Adolescents and Young Adults with Cancer	\$167,161

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Liu Y	NIGMS	1R35GM1509 41-01	10067036	59319791	7/1/23	5/31/28	Mapping the Cellular Responses to DNA Double-Strand Breaks Using On-Demand CRISPR Technologies and High-Resolution Fluorescence Microscopy	\$385,000
Lu Y	NCI	1R61CA27855 9-01	10065194	59319750	6/1/23	5/31/26	Vesicle Epitope Transcript Sequencing (VET-Seq): Droplet-Based Multiomic Profiling Platform for Single Vesicle Analysis	\$243,486
Lumpkins C	NHGRI Masonic Cancer Center #	5R01HG01191 6-02	10067717	54505502	9/21/22	6/30/26	Genetic Counseling Processes Result in Outcomes (GC-PRO) Study	\$34,185
Lussier Y	VA	IPAOSHEROF F .50FTE	10064930	55402731	4/1/22	9/30/24	Clinical Informatics and Data Management to Improve Healthcare Solution Development and Implementation (IPA: Osheroff)	\$224,694
Maese L	NCI Massachuse tts General Hospital #	1U01CA24368 8-01	10052279	54903456	9/18/19	8/31/24	AYA-RISE Intervention: Risk Information and Screening Education for Adolescents and Young Adults with Cancer Predisposition Syndromes	\$82,496
Maese L	NCI Public Health Institute on behalf of COG #	U01CA180886	10054509	54902839	10/24/19	2/28/25	NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)	\$213,535

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Maese L	NCI Public Health Institute on behalf of COG #	U10CA180886	10061617	54903204	3/1/21	2/28/25	COG Workorder to the Non-Industry Master: Per Case Reimbursement via NIH Flowthrough Mechanism: COG NCTN Network Group Operations Center	\$81,000
Maese L	NCI Public Health Institute on behalf of COG #	UG1CA189955	10063943	54903292	8/1/21	7/31/25	Children's Oncology Group NCI Community Oncology Research Program	\$4,000
Maese L	St. Baldrick's Foundation Winship Cancer Institute #	696761	10057109	54505577	7/1/20	6/30/25	Consortium for Childhood Cancer Predisposition	\$29,119
Maity A & Schure L (Curebiotech)	NCI Curebiotech #	5R41CA268252-01 NCE	10066791	54903353	9/1/22	8/31/24	Combination of CB101 and Radiation Therapy in Head and Neck Squamous Cell Carcinoma	\$50,937
Marth G	NHGRI Frameshift Genomics #	1R41HG012536-01 NCE	10062720	54903332	7/14/22	12/31/23	Web-Based Platform to Support Team-Based Genome Diagnostics	\$15,097
Marth G	NHGRI Frameshift Genomics #	1R44HG012885-01	10068928	54903508	9/15/23	8/31/25	State-of-the-Art Web Platform for Collaborative, Longitudinal Genome Diagnostics	\$203,115
Marth G & Tristani-Firouzi M (University of Utah)	NHGRI	5R01HG012286-02	10061038	59318530, 59318531	2/1/22	1/31/27	Calypso: A Web Software System Supporting Team-Based, Longitudinal Genomic Diagnostic Care	\$908,133
Marth G & Underhill H	NINDS	1UG3NS132134-01	10065990	59010051	4/1/23	3/31/25	Reference-Free Computational Algorithm for Comprehensive Somatic Mosaic Mutation Detection	\$384,588

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Marth G & Varley K & Welm B	NCI	5U01CA21761 7-05 NCE	10047239	59007415, 59007425, 59007435, 59007445	9/6/18	8/31/24	Longitudinal Models of Breast Cancer for Studying Mechanisms of Therapy Response and Resistance	\$194,287
Matsen C	PCORI Alliance #	N/A	10045771	50303274	2/1/17	2/1/24	Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: Phase III Prospective Randomized Trial	\$3,218
McIntosh M	NIGMS	5R35GM1364 30-04	10053631	59316611	4/1/20	1/31/25	Development and Application of Nicotinic Acetylcholine Receptor Targeted Peptides for Biomedical Research	\$449,875
McIntosh M	NIDA Barrow Neurological Institute #	7R01DA04274 9-06 NCE	10064588	54505477, 54903249	7/1/22	1/15/24	Relevance of alpha-Conotoxin MII Sensitive Nicotinic Receptor Subtypes to Nicotine Addiction	\$17,118
McMahon M	NCI	5R01CA13126 1-12	10064839	59319300	12/16/22	11/30/27	Studying the Initiation, Progression and Therapy of Lung Cancer in Mouse Models	\$346,500
McMahon M	NCI	3R01CA13126 1-12S1	10064839DS1 .11	59319301	12/16/22	11/30/27	Studying the Initiation, Progression and Therapy of Lung Cancer in Mouse Models : Diversity Supplement (Fellow: Martinez)	\$22,427
Mendoza M	NCI	5R01CA25579 0-02	10060936	59318740, 59318741	5/16/22	4/30/27	Cancer Invasion: Reciprocity Between the Extracellular Matrix and Intrinsic ERK Signaling	\$503,421
Mendoza M	NCI	3R01CA25579 0-02S1	10060936DS1 .2	59318742	5/1/23	4/30/27	Cancer Invasion: Reciprocity Between the Extracellular Matrix and Intrinsic ERK Signaling : Diversity Supplement (Fellow: Shaelling)	\$32,904

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Mendoza M	NIGMS	5R01GM141372-02	10062133	59318690	5/10/22	3/31/27	Kinase Control of Synergistic Cell Migration Mechanics	\$307,750
Mendoza M	NIGMS	3R01GM141372-02S1	10062133S1.2	59318691	5/10/22	3/31/27	Kinase Control of Synergistic Cell Migration Mechanics - Equipment Supplement: CSUX-A1 Confocal/TIRF Microscope	\$66,515
Miles R	NCI Children's Hospital of Philadelphia #	2R01CA193776-06	10064456	54903465	2/7/23	1/31/28	Improving Risk Allocation and Developing Novel Therapies for Children with T-Cell Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma	\$12,193
Millar M	CDC	1NU58DP007131-02-00	10064602	59006507	6/30/22	6/29/27	Cancer Prevention and Control Program Three: National Program of Cancer Registries	\$270,000
Miller M	NIGMS	5R35GM142749-03	10059244	59317861	8/1/21	5/31/26	Mechanical Activities Ensuring Accurate Chromosome Segregation	\$381,250
Mooney K & Kolb N (University of Vermont) & Smith A (Massey Cancer Center)	NCI University of Vermont #	5R01CA247517-03	10056898	54505161	5/6/21	4/30/26	Remote Monitoring of Management of Chemotherapy Induced Peripheral Neuropathy	\$284,395
Murtaugh M & Nygaard I (University of Utah)	NCATS	1K12TR004413-01	10065482		7/1/23	6/30/28	Clinical and Translational Science Awards (CTSA) K12 Program at University of Utah: Early Career Faculty Development Program	\$335,827
Myers B	NIGMS	5R35GM133672-05	10051459	59316350	8/7/19	7/31/24	Signal Transduction in the Primary Cilium: Hedgehog and Beyond	\$381,250

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Myers B	ACS	RSG-22-077-01-CCB	10063137	51200197	7/1/22	6/30/26	Overcoming Drug Resistance in Hedgehog Pathway-Driven Cancers	\$198,000
O'Connell R	NIA	5R21AI16362 3-02 NCE	10059338	59317900	7/26/21	6/30/24	Metabolic Regulation of Macrophage MicroRNAs during Colitis	\$30,112
O'Connell R & Drummond M (University of Utah)	NIA	5R01AG07607 5-02	10062421	59318801, 59318800	5/15/22	4/30/27	Regulation of Macrophage Metabolism in Aged Muscle During Recovery	\$622,306
O'Connell R & Drummond M (University of Utah)	NIA	3R01AG07607 5-02S1	10062421S1.2	59318802	12/1/23	4/30/27	Regulation of Macrophage Metabolism in Aged Muscle during Recovery - Diversity Supplement (Fellow: Castro)	\$33,363
O'Connell R & Drummond M (University of Utah)	NIA	5R01AG07947 7-02	10065083	59319040, 59319041	9/1/22	5/31/27	MicroRNA Regulation of Chronic Inflammation during Aging	\$576,261
O'Connell R & Drummond M (University of Utah)	NIA	3R01AG07947 7-02S1	10065083DS1 .2	59319042	6/1/23	5/31/27	MicroRNA Regulation of Chronic Inflammation During Aging : Diversity Supplement (Fellow: Hernandez)	\$80,007
Odéen H	NIBIB	5R21EB03311 7-02	10061997	59318620	4/1/22	12/31/24	Feasibility of Transcranial Histotripsy for Pediatric Neuro-Oncology Applications using a Hemispherical Transducer	\$196,034
Odéen H	NIBIB	5R21EB03363 8-02	10063402	59318920	8/1/22	5/31/24	Real-Time Monitoring and Treatment Evaluation of MR Guided Focal Ultrasound-Mediated Non-Thermal Ablation of Brain Tumors	\$187,262

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Odéen H & Meuillet E (Microvascular Therapeutics)	NCI Microvascular Therapeutics #	1R43CA27214 9-01A1 NCE	10064039	54903364	9/19/22	8/31/24	Selectivity and Efficacy of CD90-Targeted Phase Shift Microbubbles for HIFUmediated Thermal Ablation of Brain Tumors	\$44,629
Odelberg S	MRA	1038931	10066932	51006784	6/1/23	5/31/25	Targeting ASAP1-Induced Transcription Factors in Metastatic Uveal Melanoma	\$50,000
Okuyemi K & Hashibe M	NCI	2R25CA24675 6-04	10064288	59206151	9/19/23	8/31/28	Utah Advanced Course On Cancer-Related Health Disparities Research, Mentoring, and Leadership	\$310,217
Olivera B & Safavi-Hemami H (University of Copenhagen) & Raghuraman S (University of Utah)	NIGMS	5R01GM1447 19-02	10064574	59318600	3/15/22	2/28/26	Conus Venom Peptides and their Molecular Targets: Using Pharmacoeconomics and Neuroethology as a Framework for Discovery	\$574,453
Olivera B & Safavi-Hemami H (University of Copenhagen) & Raghuraman S	NIGMS	3R01GM1447 19-02S1	10064574S1.2	59318601	3/1/23	2/29/24	Conus Venom Peptides and Their Molecular Targets: Using Pharmacoeconomics and Neuroethology as a Framework for Discovery : Undergraduate Summer Research Supplement (Fellow: Maughn)	\$10,811
Olivera B & Safavi-Hemami H (University of Copenhagen) & Raghuraman S	NIGMS	3R01GM1447 19-02S2	10064574S2.2	59318602	3/1/23	2/28/26	Conus Venom Peptides and Their Molecular Targets: Using Pharmacoeconomics and Neuroethology as a Framework for Discovery : Automated Peptide Synthesizer Equipment Supplement	\$153,370

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Onega T	NCI Norris Cotton Cancer Center at Dartmouth - Dartmouth-Hitchcock Medical Center #	5R37CA26393 6-03	10059421	54504970	7/15/21	6/30/25	Improving Cancer Health Equity by Targeting Physician Networks	\$20,159
Onega T	NCI UC Davis Comprehensive Cancer Center #	5P01CA15429 2-12	10061546	54505381	9/16/22	8/31/27	Advancing Equitable Risk-Based Breast Cancer Screening and Surveillance in Community Practice	\$39,920
Onega T & Ozanne E	NCI	1R01CA28240 9-01	10066553	59320000	7/25/23	6/30/28	Community Services Navigation to Advance Health Equity in Breast Cancer Screening	\$638,074
Onega T & Wang F (Louisiana State University)	NCI	5R01CA26799 0-02	10061018	59318590	2/1/22	1/31/27	Access, Utilization and Outcomes of Cancer Services in the Era of Telemedicine	\$354,662
O'Neil B	NCI Vanderbilt-Ingram Cancer Center #	5R01CA23035 2-05	10050132	54505587	4/1/19	3/31/24	Ten-Year Comparative Effectiveness and Harms of Treatments for Prostate Cancer	\$22,186
O'Neil B	PCORI Fred Hutchinson/ University of Washington Cancer Consortium #	PCS-2017C3- 9380	10054299	54504328	2/1/19	1/31/24	Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Recurrent Bladder Cancer	\$10,000

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Ose J	NCI	5R03CA27047 3-02	10061489	59318840	6/14/22	5/31/24	Global Metabolomics Profiling, Dietary Factors, and Colorectal Cancer Risk in the NIH-Consortium of Metabolomics Studies (COMETS)	\$74,725
Owen S & O'Donoghue A (Moore's Comprehensive Cancer Center)	NCI Moore's Comprehensive Cancer Center #	5R21CA25646 0-02	10059776	54505312	2/1/22	1/31/24	Tumor-Specific Drug Activation by Pericellular Proteases	\$92,575
Ozanne E & Onega T	NCI	1R01CA28240 9-01	10066553	59320000	7/25/23	6/30/28	Community Services Navigation to Advance Health Equity in Breast Cancer Screening	\$638,074
Patel S	NHLBI National Marrow Donor Program #	U24HL138660	10064583	54903238	12/1/21	12/1/28	Phase III, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease	\$3,552
Payne A	NCI	4R37CA22414 1-06	10045663	59314540, 59314541, 59314542	2/1/18	1/31/25	Validation and Translation of a Non-Invasive, MR-Guided Breast Cancer Therapy	\$535,426
Payne A	NCI	4R37CA22414 1-06	10069874	59314543	2/1/23	1/31/25	Validation and Translation of a Non-Invasive, MR-Guided Breast Cancer Therapy	\$535,426
Payne A	NCI	1R21CA28637 5-1	TBDPayneR21	TBD	12/8/23	11/30/25	Quantitative Evaluation of Focused Ultrasound Thermal Therapy on Immunogenic Cell Death in Breast Cancer	\$179,988
Payne A & Joshi S (University of Utah)	NCI	5R01CA25968 6-02	10060984	59318550, 59318551	2/10/22	1/31/27	Tissue Viability Imaging Biomarker for use in Non-Invasive Breast Cancer Therapy	\$624,068

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Peterson R & MacRae C (Brigham and Women's Hospital)	NINDS Brigham and Women's Hospital #	5U54NS112107-05	10051015, 10055736, 10055480		8/1/19	5/31/24	Advancing Novel Cyanide Countermeasures	\$515,268
Peterson R & Yeh J (Massachusetts General Hospital)	NIGMS	2R01GM134069-05	10067612	59316382	6/3/23	8/31/27	Advancing Gene-Editing Nucleases for Diverse Zebrafish Applications	\$492,804
Playdon M	NINR Cedars-Sinai Medical Center #	5R01NR018762-04	10054016	54903001	5/28/20	3/31/24	Novel Biomarkers for Cancer-Related Fatigue: Integrating Metabolomics, Genomics and Behaviors	\$185,434
Playdon M	ACS Ohio State University Comprehensive Cancer Center #	RSG-20-124-01-CCE	10057174	54505115	1/1/21	12/31/24	Metabolomic Profiles of Insulinemic Dietary Patterns and Colorectal Cancer Risk: A Consortium of Metabolomics Studies (COMETS)	\$102,819
Playdon M & Ulrich C & Summers S	NCI	5U01CA272529-02	10063221	59009722, 59009732, 59009742, 59010292	9/2/22	8/31/27	Ceramides as Novel Drivers of Metabolic Dysfunction and Colorectal Cancer	\$950,923
Poppe M	NCI Rutgers Cancer Institute of New Jersey #	P30CA072720	10041245	54503252	4/29/16	10/1/24	TRI-Fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : Phase II Trial (TRIUMPH-T Trial)	\$301

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Poppe M	NCI Alliance #	5UG1CA1898 23-10	10065554	54505810	10/1/23	7/31/24	Alliance for Clinical Trials in Oncology NCI Community Oncology Research Program (NCORP) Research Base	\$32,120
Potter L	NCI	4R00CA25260 4-03	10069832	59320390	9/19/23	8/31/26	Using mHealth to Investigate Intersectionality and Health Behaviors: Implications for Conceptual Models and Cancer Prevention Interventions for Marginalized Populations	\$249,000
Pulsipher M & Switzer G (University of Pittsburgh)	NHLBI National Marrow Donor Program #	R01HL131731	10064998	51006515	3/24/22	6/30/25	Identifying Predictors of Poor Health-Related Quality-of-Life among Pediatric Hematopoietic Stem Cell Donors	\$350
Pulsipher M & Williams D (Boston Children's Hospital)	NHLBI Dana-Farber Brigham Cancer Center #	4UG3HL15756 4-02	10065946	TBD	4/1/22	3/31/24	Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia	\$161,388
Quinlan A	NHGRI	5R01HG01075 7-04	10053964	59316710	5/1/20	2/29/24	Scalable Detection and Interpretation of Structural Variation in Human Genomes	\$692,048
Quinlan A	NHGRI	5R01HG01225 2-02	10059581	59318490	2/2/22	1/31/27	New Algorithms and Tools for Large-Scale Genomic Analyses	\$625,032
Quinlan A & Aston K (University of Utah) & Hotaling J (University of Utah)	NICHD	5R01HD10611 2-03	10059567	59318150	9/1/21	5/31/26	GEMS: Genomic Approach to Connecting Elevated Germline Mutation Rates with Male Infertility and Somatic Health	\$762,315

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Rapaport M	NCI	1R21CA26345 3-01 NCE	10061403	59700370	9/10/21	8/31/24	mProstate: Massage for Prostate Cancer-Related Fatigue	\$152,965
Roh-Johnson M	NCI	5R37CA24799 4-03	10056240	59317401	2/1/21	1/31/26	Mitochondrial Lateral Transfer during Metastasis	\$341,867
Rondina M	NHLBI University of Iowa #	1R01HL16708 7-01	10062337	54505727	4/11/23	3/31/27	Determinants of Cardioprotection by Circulating Prohibitin-1 during Sepsis	\$20,174
Rondina M	NHLBI Oklahoma Medical Research Foundation #	5R35HL14523 7-05	10064187	54903383	1/1/22	12/31/25	Translational Control of Megakaryocyte and Platelet Gene Expression in Disease	\$448,008
Rothwell E & Tabery J (University of Utah)	NHGRI	5RM1HG0090 37-08	10054087	59008341	5/16/16	5/31/24	University of Utah Center of Excellence in ELSI Research (UCEER) -	\$991,250
Round J	NIDDK	5R01DK12433 6-04	10053701	59316790	5/8/20	2/29/24	Mechanisms of Fungal Involvement during Intestinal Disease	\$445,880
Round J	NIDDK	5R01DK12431 7-04	10053831	59316800	5/6/20	2/29/24	Bacteriophage Pathobiology of Inflammatory Bowel Disease	\$612,805
Round J	NCCIH	5R01AT01142 3-03	10058156	59317840	6/15/21	5/31/26	Microbiota-Immune Interactions that Promote Intestinal Homeostasis	\$606,053
Rutter J	NIGMS	5R35GM1318 54-05	10049863	59315770	4/1/19	3/31/24	Mitochondrial Biochemistry: From Mechanisms to Disease	\$381,252
Rutter J	NIGMS	3R35GM1318 54-05S1	10049863DS1 .4	59315771	4/1/22	3/31/24	Mitochondrial Biochemistry: From Mechanisms to Disease : Diversity Supplement (Fellow: Cedeno-Rosario)	\$122,606

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Rutter J	HHMI	N/A	99999993	HHMI	9/1/15	11/30/28	HHMI Investigator Program	\$887,061
Sanchez-Terrones B & Hutcheson K (University of Texas MD Anderson Cancer Center)	NCI University of Texas MD Anderson Cancer Center #	1R21CA27398 4-01	10066755	54505632	5/1/23	4/30/25	Hypoglossal Neuropathy in the Pathogenesis of Radiation Associated Dysphagia (hRAD)	\$74,461
Schiffman J	NCI University of Michigan Rogel Cancer Center #	5P50CA27217 0-02	10062505	54505739, 54505740	1/1/23	8/31/27	Genetics and Genomics of Leiomyosarcoma (LMS): Improved Understanding of Cancer Biology and New Approaches to Diagnosis and Treatment - Project 2: Understanding the Role of TP53 in LMS Development	\$163,547
Shcheglovitov O	NCI	1R21CA27977 3-01	10065205	59319920, 59319921	4/6/23	3/31/25	Regulation of Glioblastoma Cells by GABAergic Neurons in Human Organoid-Tumor Chimeras	\$215,811
Shcheglovitov O	NINDS	5R01NS12384 9-03	10059460	59318250, 59318251	8/1/21	5/31/26	Assembly and Characterization of Human Cortico-Striatal Neural Networks	\$532,100
Shen P	NIGMS	5R35GM1337 72-05	10051112	59316030	8/1/19	5/31/24	Visualizing the Mechanisms of Protein Quality Control	\$381,250
Shen P	NIGMS	3R35GM1337 72-05S1	10051112DS1 .4	59316032	6/1/22	5/31/24	Visualizing the Mechanisms of Protein Quality Control : Diversity Supplement (Fellow: Ferrell)	\$67,165
Shen P	NIGMS	3R35GM1337 72-02S1 NCE	10051112S1.2	59316031	6/1/20	5/31/24	Visualizing the Mechanisms of Protein Quality Control : AKTA FPLC Instrument Supplement	\$255

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Smith J	NCI Robert H. Lurie Comprehensive Cancer Center #	5R37CA25587-5-03	10061966	54504919	3/1/21	2/28/26	Technology Facilitated Behavioral Intervention for Depression among Diverse Patients in Ambulatory Oncology	\$27,315
Smith K	NIA Chao Family Comprehensive Cancer Center #	R21AG067247-02 NCE	10058405	54505152	9/30/21	5/31/24	Selection in Utero and Consequences from Sex Differences in Adult Mortality: A Cohort Approach	\$66,848
Smith K	NSF	1800563 NCE	10047598	58502578	7/15/18	6/30/24	Wasatch Front Research Data Center	\$135,502
Snyder E	NCI	5R01CA23740-4-04	10055610	59316750	6/1/20	5/31/25	Lineage Specifiers Governing Pancreatic Cancer Growth and Molecular Subtype	\$342,699
Snyder E	NCI	3R01CA23740-4-04S1	10055610DS1.3	59316751	3/1/22	5/31/25	Lineage Specifiers Governing Pancreatic Cancer Growth and Molecular Subtype : Diversity Supplement (Fellow: Orellana)	\$64,749
Snyder E	NCI	2R01CA21241-5-06A1	10064220	59314052	1/1/23	12/31/27	Transcriptional Regulation of Lung Cancer Identity	\$384,271
Snyder E	ACS	RSG-21-026-01-CCG	10055337	51200184	7/1/21	6/30/25	HNF4a Regulates Pancreatic Cancer Growth, Metabolism and Molecular Subtype	\$198,000
Snyder E & Maeda Y (University of Cincinnati)	NCI University of Cincinnati #	5R01CA24031-7-04	10054121	54902903	4/1/20	3/31/25	Patho-Genetic Analysis of Invasive Mucinous Adenocarcinoma of the Lung	\$260,583
Soares H	SWOG Knight Cancer Institute #	UG1CA18997-4	10052572	54504539	8/1/19	7/31/25	SWOG NCORP Research Base	\$6,000

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Soares H	SWOG Knight Cancer Institute #	U10CA180888	10060925	54505210	4/23/19	2/28/25	SWOG Network Group Operations Center of the NCTN	\$14,300
Soares H	PCORI Holden Comprehensive Cancer Center #	RD-2020C1-20329	10062493	54505076	7/1/21	6/30/24	Comparative Effectiveness Research for Neuroendocrine Tumors (CER-NET)	\$62,725
Spike B & Welm B	DOD	W81XWH-21-1-0801; W81XWH-21-1-0802	10059202/10059205		9/15/21	9/14/24	Targeting Cripto in Breast Cancer Plasticity	\$504,929
Spike B & Welm B/ Spike B	DOD	W81XWH-21-1-0801	10059202/10059205	55900765	9/15/21	9/14/24	Targeting Cripto in Breast Cancer Plasticity - (Spike)	
Welm B & Spike B/ Welm B	DOD	W81XWH-21-1-0802	10059202/10059205	55900767	9/15/21	9/14/24	Targeting Cripto in Breast Cancer Plasticity - (Welm)	
Spivak A	NIAID	1R56AI162217-01A1 NCE	10061484	59319131, 59319261	7/25/22	6/30/24	Discovering New HIV-1 Latency Reversal Agents from Euphorbia Species	\$389,068
Starr T	NIAID	1DP2AI177890-01	10069892	59010230	8/24/23	7/31/28	Evolutionary Landscape of HIV Broadly Neutralizing Antibody Development	\$462,000
Stewart R	NINDS	5R01NS106527-05 NCE	10048472	59314700	7/1/18	6/30/24	Developmental Mechanisms Driving Cell Invasion in Pediatric Brain Cancers	\$33,040
Summers S & Edgar B	NIDDK	5R01DK131609-03	10061167	59318230	9/23/21	5/31/26	Role of Ceramides in the Intestinal Stem Cell	\$512,080

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Summers S & Holland W (University of Utah)	NIDDK	5R01DK13029 6-02	10062553	59318680	4/1/22	3/31/26	Role of Ceramides in the Pancreatic Beta Cell	\$550,023
Summers S & Ulrich C & Playdon M	NCI	5U01CA27252 9-02	10063221	59009722, 59009732, 59009742, 59010292	9/2/22	8/31/27	Ceramides as Novel Drivers of Metabolic Dysfunction and Colorectal Cancer	\$950,923
Sundquist W	NIA	5R37AI05117 4-22	10059323	59303436	4/1/22	3/31/27	Biochemistry of HIV-1 Budding	\$557,086
Sundquist W	NIAID	5U54AI17085 6-02	10062103		7/11/22	4/30/27	CHEETAH Center for the Structural Biology of HIV Infection, Restriction, and Viral Dynamics	\$5,548,917
Sundquist W & Hill C & Ullman K	NIGMS	2R01GM1120 80-09	10066736	59311435, 59311436, 59311437	7/19/23	5/31/27	ESCRT and MIT Complexes in Cytokinesis	\$364,826
Suneja G	NCI Moffitt Cancer Center #	5R01CA26897 3-03	10061255	54903398	9/20/21	8/31/26	HIV Genomic Aging Project in Oncology (HIV-GAP)	\$100,360
Swaminathan S	NCI	5R01CA08113 3-20 NCE	10046501	59309112	3/1/18	2/29/24	Post-Transcriptional Gene Regulation by EBV SM Protein	\$146,315

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Sward K & Dean J (University of Utah) & Dwyer J (University of Utah) & Watt K (University of Utah)	NCATS	5U24TR00431 5-02	10064939	59009762	9/23/22	8/31/27	Helping to End Addiction Long-Term Effectiveness Research Network (HEAL ERN): Data Coordinating Resource Center	\$3,121,104
Tan A	Leidos Biomed NRG #	HHSN2612015 0003I	10069168	54903433	3/1/23	4/30/24	PI3K Pathway Activation and its Associated Genomic Profile as Predictive Biomarkers of HPV-Related Oropharyngeal Cancer: Evaluation of NRG-HN002 and RTOG 1016	\$77,193
Tan A & Chung C (Moffitt Cancer Center)	NIDCR	5R01DE03050 8-04	10067338	59319270	9/1/22	8/31/24	Decoding Tobacco-Related Oral Cancer Ecosystem by Integrative Approach	\$457,093
Tantin D	NCATS	1R03TR00456 8-01	10066846	59319950	8/1/23	7/31/24	Configuration-Specific Cofactors of OCT4	\$154,000
Tantravahi S	Leukemia and Lymphoma Society	N/A	10047396	50303405	8/1/17	8/1/24	Master Protocol for Biomarker-Based Treatment of AML (Beat AML Trial)	\$25,878
Tavtigian S	NCI	5R01CA26497 1-02	10061258	59318570, 59318571	3/1/22	1/31/27	Upgrading Rigor and Efficiency of Germline Cancer Gene Variant Classification for the 2020s	\$538,540
Tavtigian S	NCI	3R01CA26497 1-02S1	10061258S1.2	59318572	3/1/22	1/31/27	Cloud enabled, Rigorous, Functional Assay Calibration (CERFACO)	\$220,416
Trabert B	DOD University of Washington #	HT942523101 73	10065978	54505619	4/1/23	3/31/26	Genomic Predictors of Ovarian Cancer Risk in the PLCO Trial	\$30,780

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Trabert B	DOD	HT942523102 47	10065979	55900793	9/15/23	9/14/26	Understanding the Interplay of Aspirin and Other Commonly Used Medication and the Potential for Ovarian Cancer Chemoprevention	\$197,410
Trabert B	DOD Moffitt Cancer Center #	HT9425-23-1-0231	10066172	54903471	6/1/23	5/31/26	Role of Distress-Related Metabolic Dysfunction in Ovarian Cancer Development	\$24,643
Ullman K & Hill C & Sundquist W	NIGMS	2R01GM1120 80-09	10066736	59311435, 59311436, 59311437	7/19/23	5/31/27	ESCRT and MIT Complexes in Cytokinesis	\$364,826
Ulrich C	NCI	5P30CA04201 4-34	10053843	59008014, 59008134, 59008084, 59008114, 59008094, 59008044, 59008164, 59008034, 59008154, 59008184, 59008104, 59008024, 59008144, 59008054, 59008064, 59008074, 59008124, 59008174	5/1/20	4/30/25	Cancer Center Support Grant	\$4,199,958

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Ulrich C/ Onega T	NCI	5P30CA04201 4-34	10053843S9	59009604	5/1/22	4/30/25	Supplement to Support Expansion of Huntsman's Catchment Across Four Other States - System for Health Assessment and Population data Evaluation (SHAPE)	\$195,965
Ulrich C/ Sanchez A	NCI	5P30CA04201 4-34	10053843S8	59009464	5/1/22	4/30/25	RenalCare Cohort Study	\$190,619
Ulrich C/ Kaphingst K	NCI	3P30CA04201 4-34S1	10053843S1.3 4	59010364	5/1/23	4/30/24	Expanding the Reach of Cancer Genetic Services to Underserved Spanish-Speaking Latina Women	\$215,470
Ulrich C/ O'Neil B	NCI	3P30CA04201 4-34S2	10053843S2.3 4	59010354	5/1/23	4/30/24	Payment Reform Policy and Cancer Disparities in Delivery of Radiotherapy	\$124,997
Ulrich C/ Kepka D	NCI	3P30CA04201 4-34S3	10053843S3.3 4	59010424	5/1/23	4/30/24	Rural Community Health Center Partnerships to Develop and Implement Process for HPV Self-Collection and Follow-Up among Women Overdue for Cervical Cancer Screening	\$214,999
Ulrich C/ Ayer D	NCI	3P30CA04201 4-34S4	10053843S4.3 4	59010374	5/1/23	4/30/24	Strengthening Research, Training and Outreach Capacity in Huntsman Cancer Institute's Mountain West Service Area	\$200,000
Ulrich C/ Marth G	NCI	3P30CA04201 4-34S5	10053843S5.3 4	59010404	5/1/23	4/30/24	Harmonizing Genomic, Transcriptomic, and Drug Response Data across Pre-Clinical Models of Cancer to Support Machine Learning Approaches for Personalized Cancer Therapy Selection	\$307,975

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Ulrich C/ Lex A	NCI	3P30CA04201 4-34S6	10053843S6.3 4	59010414	5/1/23	4/30/24	Enhancing Loon: Increasing Robustness and Generalizing Input Formats for a Visualization Tool for Large-Scale Microscopy Data	\$231,000
Ulrich C/ Kimani S	NCI	3P30CA04201 4-33 NCE	10053843S10	59009694	9/1/22	4/30/25	Developing Global Measures of Cancer Stigma	\$70,882
Ulrich C & Hursting S (University of North Carolina)	NCI	5R01CA25410 8-03	10058539	59318310	9/23/21	8/31/26	Adipose Tissue-Colorectal Tumor Cross-Talk: New Targets for Breaking the Obesity-Cancer Link	\$627,486
Ulrich C & Li C (Fred Hutchinson/University of Washington Cancer Consortium)	NCI	5R01CA20737 1-05 NCE	10043057	59314030	4/1/17	3/31/24	Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer Recurrence	\$369,517
Ulrich C & Shibata D (University of Tennessee) & Figueiredo J (Cedars-Sinai Medical Center) & Siegel E (Moffitt Cancer Center) & Toriola A (Washington University in St. Louis) & Schneider M (Heidelberg University)	NCI	5U01CA20611 0-08	10059766	59009243	9/19/16	8/31/26	Transdisciplinary Team Science in Colorectal Cancer Prognosis: The ColoCare Study	\$1,848,714
Ulrich C & Summers S & Playdon M	NCI	5U01CA27252 9-02	10063221	59009722, 59009732, 59009742, 59010292	9/2/22	8/31/27	Ceramides as Novel Drivers of Metabolic Dysfunction and Colorectal Cancer	\$950,923

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Underhill H	NCI	5R37CA24618 3-04	10052285	59316580	2/1/20	1/31/25	Circulating Cell-Free DNA as a Personalized Biomarker to Diagnose and Monitor Glioblastoma	\$341,867
Underhill H & Marth G	NINDS	1UG3NS1321 34-01	10065990	59010051	4/1/23	3/31/25	Reference-Free Computational Algorithm for Comprehensive Somatic Mosaic Mutation Detection	\$384,588
Vaklavas C & Welm A	NCI	5R21CA26334 5-02	10061969	59318560	4/1/22	3/31/24	Feasibility Trial of Functional Precision Cancer Medicine to Inform Treatment Selection in Metastatic Breast Cancer	\$211,494
Vaklavas C & Welm A	DOD	W81XWH-22-1-0123; W81XWH-22-1-0124	10062006; 10062007		7/1/22	6/30/26	Toward Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of Triple-Negative Breast Cancer	\$1,844,757
Vaklavas C & Welm A/ Vaklavas C	DOD	W81XWH-22-1-0124	10062006; 10062007	55900774	7/1/22	6/30/26	Toward Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of Triple-Negative Breast Cancer - (Vaklavas)	
Welm A & Vaklavas C/ Welm A	DOD	W81XWH-22-1-0123	10062006; 10062007	55900777	7/1/22	6/30/26	Toward Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of Triple-Negative Breast Cancer - (Welm)	
Varley K	ACS	RSG-18-197-01-DMC NCE	10049535	51200168	1/1/19	12/31/23	Targeting Transcription Factors in Triple Negative Basal Breast Cancer	\$36,702

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Varley K & Bernard P	NCI	5UH3CA26222 1-02	10062203	59009612	8/1/22	7/31/25	Validation of the MHC II Immune Activation Assay in Breast Cancer	\$344,474
Varley K & Debnath J (UCSF Helen Diller Family Comprehensive Cancer Center) & Li C (Fred Hutchinson/University of Washington Cancer Consortium) & Welm A & Ghajar C (Fred Hutchinson/University of Washington Cancer Consortium)	DOD	W81XWH-22-2-0005; W81XWH-22-2-0004; W81XWH-22-2-0003; W81XWH-22-2-0006; W81XWH-22-2-0007	10061993/10062012		8/1/22	7/31/26	Targeting and Reprogramming DTCs to Prevent Lethal Metastasis (TRANCE) Consortium	\$2,950,313
Varley K & Debnath J (UCSF Helen Diller Family Comprehensive Cancer Center) & Li C (Fred Hutchinson/University of Washington Cancer Consortium) & Welm A & Ghajar C (Fred Hutchinson/University of Washington Cancer Consortium)/ Varley K	DOD	W81XWH-22-2-0004	10061993/10062012	55900779, 55900780	8/1/22	7/31/26	Targeting and Reprogramming DTCs to Prevent Lethal Metastasis (TRANCE) Consortium - Prevention of Lethal Metastatic Breast Cancer by Identifying and Eradicating Clinically Relevant Disseminated Tumor Cells (Varley)	

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Welm A & Debnath J (UCSF Helen Diller Family Comprehensive Cancer Center) & Li C (Fred Hutchinson/University of Washington Cancer Consortium) & Varley K & Ghajar C (Fred Hutchinson/University of Washington Cancer Consortium)/ Welm A	DOD	W81XWH-22-2-0005	10061993/10062012	55900786	8/1/22	7/31/26	Targeting and Reprogramming DTCs to Prevent Lethal Metastasis (TRANCE) Consortium - Prevention of Lethal Metastatic Breast Cancer by Identifying and Eradicating Clinically Relevant Disseminated Tumor Cells (Welm)	
Varley K & Marth G & Welm B	NCI	5U01CA217617-05 NCE	10047239	59007415, 59007425, 59007435, 59007445	9/6/18	8/31/24	Longitudinal Models of Breast Cancer for Studying Mechanisms of Therapy Response and Resistance	\$194,287
Welm A	NCI	5R01CA223245-05 NCE	10047999	59314840	7/1/18	6/30/24	Role of RON Kinase in Anti-Tumor Immune Responses	\$35,392
Welm A	Susan G. Komen Foundation	SAC220226	10064393	51006631	3/10/23	3/9/26	Augmenting Effects of Immunotherapy for Metastatic Breast Cancer	\$202,195
Welm A & Lewis M (Baylor College of Medicine) & Welm B	NCI	2U54CA224076-01	10067419		8/21/23	6/30/28	PDX Trial Center for Breast Cancer Therapy	\$1,187,489
Welm A & Lewis M (Baylor College of Medicine) & Welm B/ Welm A	NCI	2U54CA224076-01	10067419	59007785	8/21/23	6/30/28	PDX Trial Center for Breast Cancer Therapy - Research Project 2: Identify and Validate Efficacious Therapies for Metastatic Breast Cancer	

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Welm A & Lewis M (Baylor College of Medicine) & Welm B/ Welm A	NCI	2U54CA22407 6-01	10067419	59007735	8/21/23	6/30/28	PDX Trial Center for Breast Cancer Therapy - Admin Core	
Welm A & Lewis M (Baylor College of Medicine) & Welm B/ Marth G	NCI	2U54CA22407 6-01	10067419	59007745	8/21/23	6/30/28	PDX Trial Center for Breast Cancer Therapy - Bioinformatics Core	
Welm A & Lewis M (Baylor College of Medicine) & Welm B/ Welm A & Lewis M(Baylor College of Medicine)	NCI	2U54CA22407 6-01	10067419	59007755	8/21/23	6/30/28	PDX Trial Center for Breast Cancer Therapy - PDX Core	
Welm A & Lewis M (Baylor College of Medicine) & Welm B/ Welm A	NCI	2U54CA22407 6-01	10067419	59007765	8/21/23	6/30/28	PDX Trial Center for Breast Cancer Therapy - Pilot Projects and Trans-Network Activities Core	
Welm A & Vaklavas C	NCI	5R21CA26334 5-02	10061969	59318560	4/1/22	3/31/24	Feasibility Trial of Functional Precision Cancer Medicine to Inform Treatment Selection in Metastatic Breast Cancer	\$211,494
Welm B & Varley K & Marth G	NCI	5U01CA21761 7-05 NCE	10047239	59007415, 59007425, 59007435, 59007445	9/6/18	8/31/24	Longitudinal Models of Breast Cancer for Studying Mechanisms of Therapy Response and Resistance	\$194,287
Werner M	NIGMS	1R35GM1507 20-01	10066539	59320050	7/25/23	5/31/28	Chromatin and Metabolic Regulation of Plasticity in a Predatory Nematode	\$385,000

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Werner T	Gynecologic Oncology Group	M13694	10039011	50302858	2/26/15	2/1/26	Phase III, Placebo-Controlled Study of Carboplatin/Paclitaxel with or without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	\$7,989
Werner T	Gynecologic Oncology Group	PR305017CG OG3012	10043591	50303124	6/1/16	1/1/28	Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	\$21,456
Werner T	Gynecologic Oncology Group	YO39523	10045573	50303239	2/1/17	1/1/24	Phase III, Multicenter, Randomized, Study of Atezolizumab versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	\$8,114

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Werner T	Gynecologic Oncology Group	CO-338-087	10050039	50303551	4/1/18	4/1/25	Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy	\$14,442
Werner T	NRG	NRG ONCOLOGY CLINICAL TRIAL FI	10053041	50303797	3/1/19	2/28/25	NRG Oncology Clinical Trial Fixed Price Subaward LAPS NRG MSA and Amendment	\$59,830
Werner T	Gynecologic Oncology Group	GCT1015-05	10054687	50303842	7/1/19	7/1/26	Phase Ib/II Open-Label Trial of Tisotumab Vedotin (Hu-Max-TF-ADC) in Combinations with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer	\$5,992
Werner T	Gynecologic Oncology Group Genentech #	N/A	10061927	50304300	5/1/21	5/1/28	Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors	\$37,402
Wetter D	NCI Georgia State University #	5R01CA23700 4-05	10051560	54504242	5/1/19	4/30/24	Mindfulness-Based Smoking Cessation Mobile App Designed for Low-Income Smokers	\$8,660
Wetter D	PCORI	PCS-2017C2-7613	10047919	51005854, 51006089	10/1/18	10/31/25	Multi-Level Interventions for Increasing Tobacco Cessation at Federally Qualified Health Centers (FQHCs)	\$1,379,592

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Wetter D & Adams A (Montana State University)	NCI	1U54CA28081 2-01	10066095		5/3/23	4/30/28	Multi-Sector, Multi-Level Interventions for Improving Cancer Prevention and Control Addressing Persistent Poverty	\$1,968,971
Wetter D & Adams A (Montana State University)/ Schlechter C & Estabrooks P & Wetter D	NCI	1U54CA28081 2-01	10066095	59010161, 59010171	5/3/23	4/30/28	Multi-Sector, Multi-Level Interventions for Improving Cancer Prevention and Control Addressing Persistent Poverty - Project 1: Multi-Level Interventions for Addressing Tobacco Cessation and SDOH in Community Health Centers (CHCs)	
Wetter D & Adams A (Montana State University)/ Estabrooks P & Adams A(Montana State University) & Tomayko E(Montana State University)	NCI	1U54CA28081 2-01	10066095	59010181	5/3/23	4/30/28	Multi-Sector, Multi-Level Interventions for Improving Cancer Prevention and Control Addressing Persistent Poverty - Project 2: Delivery of Turtle Island Tales to Promote Family Wellness	
Wetter D & Adams A (Montana State University)/ Wetter D & Adams A(Montana State University)	NCI	1U54CA28081 2-01	10066095	59010101	5/3/23	4/30/28	Multi-Sector, Multi-Level Interventions for Improving Cancer Prevention and Control Addressing Persistent Poverty - Administrative Core	
Wetter D & Adams A (Montana State University)/ Okuyemi K & Held S(Montana State University)	NCI	1U54CA28081 2-01	10066095	59010131	5/3/23	4/30/28	Multi-Sector, Multi-Level Interventions for Improving Cancer Prevention and Control Addressing Persistent Poverty - Career Enhancement Core	

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Wetter D & Adams A (Montana State University)/ Del Fiol G & Skewes M(Montana State University)	NCI	1U54CA28081 2-01	10066095	59010141, 59010151	5/3/23	4/30/28	Multi-Sector, Multi-Level Interventions for Improving Cancer Prevention and Control Addressing Persistent Poverty - Development Core	
Wetter D & Adams A (Montana State University)/ Greene T & Smith J	NCI	1U54CA28081 2-01	10066095	59010121	5/3/23	4/30/28	Multi-Sector, Multi-Level Interventions for Improving Cancer Prevention and Control Addressing Persistent Poverty - Research and Methods Core	
Wetter D & Del Fiol G	NIMHD	5U01MD01742 1-02 NCE	10062178	59009312	1/1/22	11/30/24	SCALE UP Utah II: Community-Academic Partnership to Address COVID-19 Testing and Vaccination among Utah Community Health Centers	\$751,185
Wetter D & Wu Y	NICHHD	3OT2HD10809 7-01S1 NCE	10061542S1.1	59009143, 59009144	7/21/21	7/20/24	SCALE-UP Counts: A Health Information Technology Approach to Increasing COVID-19 Testing in Elementary and Middle Schools Serving Disadvantaged Communities	\$229,623
Williams M & Evavold B	NIAID	1R01AI17225 3-01A1	10066240	59319710, 59319711	4/1/23	3/31/28	Deconstructed T Cell Antigen Recognition: Separation of Affinity from Bond Lifetime	\$717,941
Wu Y	NCI	5R01CA24467 4-04	10052225	59316550	3/1/20	2/28/25	Personalized Approach to Skin Cancer Prevention among Adolescents	\$584,156
Wu Y	ACS	RSG-19-121- 01-CPPB	10053180	51200175	1/1/20	12/31/24	Family-Focused Melanoma Preventive Intervention for Children of Survivors	\$197,250
Wu Y & Hay J (Memorial Sloan-Kettering Cancer Center)	NCI	1R01CA26630 2-01A1	10064795	59319581	4/1/23	3/31/28	Optimization of a Personalized Skin Cancer Risk Intervention for at Risk Young Adults	\$671,963

**Huntsman Cancer Institute Center Wide
Data Table 2A - Active Funded Grants as of 12/31/2023**

PI	Specific Funding Source	Project Number	PID/DSS	University of Utah Project #	Project Start Date	Project End Date	Project Title	Full Annual Project Total Costs (Outgoing Subs Included) \$
PEER-REVIEWED RESEARCH PROJECTS								
Wu Y & Wetter D	NICHD	3OT2HD10809 7-01S1 NCE	10061542S1.1	59009143, 59009144	7/21/21	7/20/24	SCALE-UP Counts: A Health Information Technology Approach to Increasing COVID-19 Testing in Elementary and Middle Schools Serving Disadvantaged Communities	\$229,623
Yang J	DOD	W81XWH-20-1- 0573 NCE	10053251	55900720	7/1/20	6/30/24	KT-1 Paired with Multivalent Polymer-Anti-PD-L1 Peptide Hybrid: A Synergistic Chemoimmunotherapy for Treatment of Triple-Negative and Metastatic Breast Cancer	\$371,174
Yap J	NCI MultiFunction al Imaging #	5R44CA25752 2-02	10062708	54903326	9/1/22	8/31/25	Dual-Tracer PET Tumor Imaging	\$220,022
Young A	NCI	5R00CA24606 1-04	10063044	59318410	2/1/20	11/30/24	Developing Strategies to Inhibit Cancer Immunotherapy-Induced Immune-Related Adverse Events without Impeding Anti-Tumor Immunity	\$249,000
Yu M & Weiss J (University of Utah)	NIAMS	5R01AR07135 8-05 NCE	10045626	59314671, 59314670	5/5/18	4/30/24	Targeting Collagen Mechanical Damage Using Collagen Hybridizing Peptides	\$72,675
Zangle T & Judson-Torres R	NCI	1R01CA27665 3-01A1	10067459	59320340, 59320341, 59320342	9/12/23	8/31/28	Development and Pre-Clinical Validation of Quantitative Imaging of Cell State Kinetics (QuICK) for Functional Precision Oncology	\$390,494
							Peer-Reviewed Research Subtotals:	\$121,340,285